Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons™

Open Access. Powered by Scholars. Published by Universities.®

Alzheimer's disease

2022

Discipline
Institution
Publication
Publication Type

Articles 31 - 35 of 35

Full-Text Articles in Medicine and Health Sciences

Investigating The Mitochondrial Protein Mitoneet In C. Elegans Models Of Aging And Alzheimer's Disease, Jacob Ryan Boos Jan 2022

Investigating The Mitochondrial Protein Mitoneet In C. Elegans Models Of Aging And Alzheimer's Disease, Jacob Ryan Boos

Graduate Theses, Dissertations, and Problem Reports

Oxidative stress is an imbalance between reactive oxygen species production and elimination, favoring the former. Reactive oxygen species serve as important signaling molecules for physiological homeostasis. However, when produced in excess, these once important signaling molecules become detrimental, disrupting cellular functions, and ultimately leading to cell death. In aging, reactive oxygen species production is increased, accompanied with reductions in oxidative stress resistance, increasing the risk for developing age-related diseases including cardiovascular disease, cancer, stroke, and neurodegenerative diseases. The outer mitochondrial membrane iron-sulfur cluster containing protein mitoNEET (CISD1; gene CISD1) has shown to be a mediator of mitochondrial function and …

Go to article

Cerebrospinal Fluid Levels Of Fatty Acid–Binding Protein 3 Are Associated With Likelihood Of Amyloidopathy In Cognitively Healthy Individuals, Kunal Dhiman, Victor L. Villemagne, Christopher Fowler, Pierrick Bourgeat, Qiao-Xin Li, Steven Collins, Christopher C. Rowe, Colin L. Masters, David Ames, Kaj Blennow, Henrik Zetterberg, Ralph N. Martins, Veer Gupta Jan 2022

Cerebrospinal Fluid Levels Of Fatty Acid–Binding Protein 3 Are Associated With Likelihood Of Amyloidopathy In Cognitively Healthy Individuals, Kunal Dhiman, Victor L. Villemagne, Christopher Fowler, Pierrick Bourgeat, Qiao-Xin Li, Steven Collins, Christopher C. Rowe, Colin L. Masters, David Ames, Kaj Blennow, Henrik Zetterberg, Ralph N. Martins, Veer Gupta

Research outputs 2022 to 2026

Introduction: Fatty acid–binding protein 3 (FABP3) is a biomarker of neuronal membrane disruption, associated with lipid dyshomeostasis—a notable Alzheimer's disease (AD) pathophysiological change. We assessed the association of cerebrospinal fluid (CSF) FABP3 levels with brain amyloidosis and the likelihood/risk of developing amyloidopathy in cognitively healthy individuals. Methods: FABP3 levels were measured in CSF samples of cognitively healthy participants, > 60 years of age (n = 142), from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). Results: FABP3 levels were positively associated with baseline brain amyloid beta (Aβ) load as measured by standardized uptake value ratio (SUVR, standardized β …

Go to article

Exploring Discordant Low Amyloid Beta And High Neocortical Tau Positron Emission Tomography Cases, Natasha Krishnadas, Vincent Doré, Simon M. Laws, Tenielle Porter, Fiona Lamb, Svetlana Bozinovski, Victor L. Villemagne, Christopher C. Rowe Jan 2022

Exploring Discordant Low Amyloid Beta And High Neocortical Tau Positron Emission Tomography Cases, Natasha Krishnadas, Vincent Doré, Simon M. Laws, Tenielle Porter, Fiona Lamb, Svetlana Bozinovski, Victor L. Villemagne, Christopher C. Rowe

Research outputs 2022 to 2026

Introduction: Neocortical 3R4R (3-repeat/4-repeat) tau aggregates are rarely observed in the absence of amyloid beta (Aβ). 18F-MK6240 binds specifically to the 3R4R form of tau that is characteristic of Alzheimer's disease (AD). We report four cases with negative Aβ, but positive tau positron emission tomography (PET) findings. Methods: All Australian Imaging, Biomarkers and Lifestyle study of aging (AIBL) study participants with Aβ (18F-NAV4694) and tau (18F-MK6240) PET scans were included. Centiloid < 25 defined negative Aβ PET (Aβ–). The presence of neocortical tau was defined quantitatively and visually. Results: Aβ– PET was observed in 276 participants. Four of these participants (one cognitively unimpaired [CU], two mild cognitive impairment [MCI], one AD) had tau tracer retention in a pattern consistent with Braak tau stages V to VI. Fluid biomarkers supported a diagnosis of AD. In silico analysis of APP, PSEN1, PSEN2, and MAPT genes did not identify relevant functional mutations. Discussion: Discordant cases were infrequent (1.4% of all Aβ– participants). In these cases, the Aβ PET ligand may not be detecting the Aβ that is present.

Go to article

Plasma P217+Tau Versus Nav4694 Amyloid And Mk6240 Tau Pet Across The Alzheimer's Continuum, Vincent Doré, James D. Doecke, Ziad S. Saad, Gallen Triana-Baltzer, Randy Slemmon, Natasha Krishnadas, Pierrick Bourgeat, Kun Huang, Samantha Burnham, Christopher Fowler, Stephanie R. Rainey-Smith, Ashley I. Bush, Larry Ward, Jo Robertson, Ralph N. Martins, Colin L. Masters, Victor L. Villemagne, Jurgen Fripp, Hartmuth C. Kolb, Christopher C. Rowe Jan 2022

Plasma P217+Tau Versus Nav4694 Amyloid And Mk6240 Tau Pet Across The Alzheimer's Continuum, Vincent Doré, James D. Doecke, Ziad S. Saad, Gallen Triana-Baltzer, Randy Slemmon, Natasha Krishnadas, Pierrick Bourgeat, Kun Huang, Samantha Burnham, Christopher Fowler, Stephanie R. Rainey-Smith, Ashley I. Bush, Larry Ward, Jo Robertson, Ralph N. Martins, Colin L. Masters, Victor L. Villemagne, Jurgen Fripp, Hartmuth C. Kolb, Christopher C. Rowe

Research outputs 2022 to 2026

Introduction: We evaluated a new Simoa plasma assay for phosphorylated tau (P-tau) at aa217 enhanced by additional p-tau sites (p217+tau). Methods: Plasma p217+tau levels were compared to 18F-NAV4694 amyloid beta (Aβ) positron emission tomography (PET) and 18F-MK6240 tau PET in 174 cognitively impaired (CI) and 223 cognitively unimpaired (CU) participants. Results: Compared to Aβ− CU, the plasma levels of p217+tau increased 2-fold in Aβ+ CU and 3.5-fold in Aβ+ CI. In Aβ− the p217+tau levels did not differ significantly between CU and CI. P217+tau correlated with Aβ centiloids P =.67 (CI, P =.64; CU, P =.45) and tau SUVRMT P …

Go to article

Plasma P-Tau181/Aβ1-42 Ratio Predicts Aβ-Pet Status And Correlates With Csf-P-Tau181/Aβ1-42 And Future Cognitive Decline, Christopher J. Fowler, Erik Stoops, Stephanie R. Rainey-Smith, Eugeen Vanmechelen, Jeroen Vanbrabant, Nele Dewit, Kimberley Mauroo, Paul Maruff, Christopher C. Rowe, Jurgen Fripp, Qiao-Xin Li, Pierrick Bourgeat, Steven J. Collins, Ralph N. Martins, Colin L. Masters, James D. Doecke Jan 2022

Plasma P-Tau181/Aβ1-42 Ratio Predicts Aβ-Pet Status And Correlates With Csf-P-Tau181/Aβ1-42 And Future Cognitive Decline, Christopher J. Fowler, Erik Stoops, Stephanie R. Rainey-Smith, Eugeen Vanmechelen, Jeroen Vanbrabant, Nele Dewit, Kimberley Mauroo, Paul Maruff, Christopher C. Rowe, Jurgen Fripp, Qiao-Xin Li, Pierrick Bourgeat, Steven J. Collins, Ralph N. Martins, Colin L. Masters, James D. Doecke

Research outputs 2022 to 2026

Background: In Alzheimer's disease (AD), plasma amyloid beta (Aβ)1-42 and phosphorylated tau (p-tau) predict high amyloid status from Aβ positron emission tomography (PET); however, the extent to which combination of these plasma assays can predict remains unknown. Methods: Prototype Simoa assays were used to measure plasma samples from participants who were either cognitively normal (CN) or had mild cognitive impairment (MCI)/AD in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Results: The p-tau181/Aβ1-42 ratio showed the best prediction of Aβ-PET across all participants (area under the curve [AUC] = 0.905, 95% confidence interval [CI]: 0.86–0.95) and in CN (AUC = …

Go to article

First Prev